Join us for a WCG Beach Party at DIA. Tuesday, June 17 • 6:30-10PM. Click here to register.


Six Practices of High Performing Clinical Research Sites

By |January 26th, 2018|Insights, White Papers|

Looking Ahead to 2018: Insights into Clinical Research Trends from Our Experts

2017 was a fascinating year for those of us closely following the clinical research industry. And 2018 promises not to disappoint. Within the WIRB-Copernicus Group (WCG) family of companies, our subject matter experts are always watching regulatory, technology, and practice trends. Their observations, combined with a deep understanding of the science and practice of […]

By |December 12th, 2017|Insights, White Papers|

Compensating Participants in Clinical Research: Current thinking


Lindsay McNair, MD, MPH, MSBioethics
Chief Medical Officer
WIRB-Copernicus Group

By |October 11th, 2017|Insights, White Papers|

…But Is It Gene Therapy? Debating a (Controversial) Definition


Daniel Kavanagh, PhD
Senior Director, Biosafety and Gene Therapy
WIRB Copernicus Group

By |September 20th, 2017|Insights, White Papers|

Pragmatic Clinical Trials: What You Need to Know


Jeffrey A. Cooper, MD, MMM
Vice President, Process and Strategic Improvement
WIRB Copernicus IRB Group

By |September 13th, 2017|Insights, White Papers|

Clinical Trial Recruitment Practices: The Evolution of Ethical Considerations


Lindsay McNair, MD, MPH, MSB
Chief Medical Officer
WIRB-Copernicus Group 
David Borasky, MPH, CIP
Vice President, IRB Compliance
WIRB-Copernicus Group

By |August 23rd, 2017|Insights, White Papers|

Five Essential Considerations for Efficient Site Contracts and Payments


Russell John
Global Director of Grants Management
Clintrax Global

By |August 1st, 2017|Insights, White Papers|

Alphabetical Glossary of Terms: Gene Therapy & Immunotherapy, 2nd Edition

The purpose of this glossary is to provide clarification of the most commonly used terms related to gene therapy and immunotherapy. The terms in this glossary are listed alphabetically, with illustrations where appropriate.


Daniel Kavanagh, PhD
Senior Director, Biosafety and Gene Therapy
WCG Biosafety

By |July 28th, 2017|Insights, White Papers|

The Revised NIH Guidelines 2016: Assessing the Impact on Human Gene Transfer Clinical Trials


David W. Emery, PhD
Director, IBC Services
WCG Biosafety, A Division of the WIRB-Copernicus Group

By |June 12th, 2017|Insights, White Papers|

Choosing the Right Solution: Improving the Site Feasibility Process


Jeff Barrett, MS
Product SME, Site Feasibility Application
ePharmaSolutions, a WIRB-Copernicus Group Company